85岁及以上急性缺血性卒中患者血管内治疗后的功能结局:HERMES子研究
该研究基于HERMES协作组7项随机试验的汇总数据,纳入1764例患者,其中77例(4.4%)年龄≥85岁。结果显示,年龄与治疗对不良结局(改良Rankin量表评分5-6分,P=0.020)和死亡率(P=0.031)存在显著交互作用,但≥85岁亚组仍从血管内治疗中获益(共同比值比4.20,95%CI 1.56-11.32)。结论认为,对于病前功能独立的≥85岁患者,血管内治疗不应被 withheld。
要点
- 在≥85岁亚组中,血管内治疗与保守治疗相比,获得良好功能结局的比例更高,死亡率更低。
- 年龄与治疗对不良结局和死亡率存在显著交互作用,高龄患者总体结局更差。
- ≥85岁患者接受血管内治疗后,症状性颅内出血和再灌注率与年轻患者无显著差异。
核心结论
- 对于病前功能独立的≥85岁急性缺血性卒中患者,与保守治疗相比,血管内治疗更常获得良好功能结局且死亡率更低,并观察到年龄对结局的治疗效应修饰,因此不应在该亚组中 withheld 血管内治疗。
研究设计与样本
- HERMES协作组是对7项随机试验的荟萃分析,这些试验于2010年1月1日至2017年5月31日发表,评估了血管内治疗的疗效;共纳入1764例患者,其中77例(4.4%)年龄≥85岁。
主要发现
- 年龄与治疗对不良结局(改良Rankin量表评分5-6分,P=0.020)和死亡率(P=0.031)存在显著交互作用,高龄患者90天功能结局更差(调整共同比值比0.20,95%CI 0.13-0.33)。
- 在≥85岁亚组中观察到血管内治疗获益(共同比值比4.20,95%CI 1.56-11.32)。
- 年龄≥85岁与症状性颅内出血率(调整比值比1.92,95%CI 0.71-5.15)和再灌注率(调整比值比0.91,95%CI 0.40-2.06)无显著关联。
关键数值与推荐
- 在≥85岁亚组中,血管内治疗与保守治疗相比,共同比值比为4.20(95%CI 1.56-11.32),倾向于血管内治疗。
- 年龄与治疗对不良结局(改良Rankin量表评分5-6分)的交互作用P=0.020,对死亡率的交互作用P=0.031。
临床怎么用
- 对于病前功能独立的≥85岁急性缺血性卒中患者,不应 withheld 血管内治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies have shown endovascular treatment (EVT) for acute ischemic stroke to be effective in the elderly, despite resulting in poorer outcomes and higher rates of mortality compared with younger patients. Randomized data on the effect of advanced age on outcomes following EVT are, however, lacking. Our aim was to assess the EVT effect for ischemic stroke in patients aged ≥85 years and the influence of age on outcome in a large, randomized trial dataset. METHODS: Data were from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration, a meta-analysis of 7 randomized trials published between January 1, 2010, and May 31, 2017, that tested the efficacy of EVT. A possible multiplicative interaction effect of age on the relationship between treatment and outcome was investigated. Ordinal logistic regression tested the association between EVT and 90-day functional outcome (modified Rankin Scale, primary outcome) in patients ≥85 years. Multivariable binary logistic regression was performed to compare primary and secondary outcomes (modified Rankin Scale score of 0-2/5-6) of patients ≥85 years versus those <85 years. RESULTS: We included 1764 patients in the analysis, of whom 77 (4.4%) were ≥85 years old. A significant interaction of age and treatment on poor outcome (modified Rankin Scale score of 5-6, P=0.020) and mortality (P=0.031) was observed, with older adults having worse functional outcomes at 90 days compared with younger patients (adjusted common odds ratio, 0.20 [95% CI, 0.13-0.33]). However, a benefit of EVT was observed in the ≥85-year-old patient subgroup (common odds ratio, 4.20 [95% CI, 1.56-11.32]). Age ≥85 years was not significantly associated with differing rates of symptomatic intracerebral hemorrhage or reperfusion (adjusted odds ratio, 1.92 [95% CI, 0.71-5.15] and adjusted odds ratio, 0.91 [95% CI, 0.40-2.06], respectively). CONCLUSIONS: Patients ≥85 years old with independent premorbid function more often achieve good functional outcomes and have lower rates of mortality when treated with EVT compared with conservative management, with an observed treatment effect modification of age on outcome. EVT should therefore not be withheld in this subgroup.
引用
- McDonough RV, Ospel JM, Campbell BCV, et al. Functional Outcomes of Patients ≥85 Years With Acute Ischemic Stroke Following EVT: A HERMES Substudy. Stroke. 2022. PMID: 35703094. doi:10.1161/STROKEAHA.121.037770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。